This trial is evaluating whether Pegaspargase will improve 2 primary outcomes and 4 secondary outcomes in patients with Leukemia, Lymphocytic, Acute, L1. Measurement will happen over the course of From randomization or direct assignment (for participants who achieved a complete remission and were assigned a final risk group) to the time of relapse, death, or second malignancy, whichever came first, assessed up to 60 months..
This trial requires 560 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pegaspargase is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"Almost 20% of healthy adults are expected to develop leukemia at some point in their life. The chance of developing leukemia is higher among adolescents who develop hematologic disorders and the elderly." - Anonymous Online Contributor
"Within 3 months, leukemia had spread in 15.4% of patients. Patients with a complete remission, in contrast, had no sign of leukemia spread in either bone marrow or peripheral blood after a similar length of time. Thus, after relapse, bone marrow or peripheral blood should be tested for leukemia at the same times as bone marrow and peripheral blood in patients with complete remission." - Anonymous Online Contributor
"pegaspargase treatment is associated with common side effects including febrile neutropenia, hepatotoxicity, pancreatitis, and allergic reactions. However, these side effects rarely impede the therapy and are manageable in most cases, but when they do, patients should be hospitalized for evaluation and treatment. In this way, they can be prevented and managed." - Anonymous Online Contributor
"Results from a recent paper suggests that genetic mutations resulting in an increased number of aberrant cells may occur frequently among people who develop leukemia. A second mechanism, involving the production of a single abnormal cell, may increase the risk." - Anonymous Online Contributor
"answer: The study suggests the relevance of teaching medical students the concepts and terminology used in the context of hematologic malignancies, in order to enable students to make better decisions." - Anonymous Online Contributor
"The cure for leukemia remains elusive. Current treatment options (imatinib, fludarabine/cyclophosphamide/melphalan plus filgrastim/rituximab) have provided durable remissions in the order of many years in a substantial number of patients. However, the cure in patients is not always long-lasting, with about one third of relapsed/refractory cases dying quickly and some patients continuing to deteriorate despite new treatment. Further, more effective treatments, particularly in newly-diagnosed forms of leukemias, as well as for the more aggressive variants of B-CLL, CLL, and hairy cell leukemia, are needed urgently." - Anonymous Online Contributor
"Signs of leukemia involve the gastrointestinal tract and the skin. Signs of leukemia are often associated with malaise, anemia, weight loss, and fatigue. Signs of leukemia may be present for as long as 4 weeks." - Anonymous Online Contributor
"Approximately 22,000 people per year are diagnosed with leukemia, which makes up 8.7% of American adults. In adults, leukemia occurs most commonly in the developing world. Lymphoproliferative disorders such as lymphoma and multiple myeloma are more common in men than in women. Most frequently, leukemia occurs in older children; however, leukemia of childhood has a skewed age incidence (mean age of diagnosis: 6.8 yr) compared with newly diagnosed leukemia in adults (mean age: 61 yr)." - Anonymous Online Contributor
"It is imperative that healthcare professionals remember to listen to patients and tailor treatment to their particular needs based on a thorough medical history as well as objective laboratory measurements of the patient to ensure that the best available treatment is delivered to the cancer patient. This is especially important to remember when dealing with cancer patients who are children and adolescents. They are still developing with each growth doubling and in some cases may be in danger of developing the more serious leukemia of childhood." - Anonymous Online Contributor
"Although the prevalence of hematological malignancies is not significantly correlated with a family history of cancer, the risk in the offspring is increased to the same extent as seen in other cancers. Therefore, the family history does not suffice as a screening tool in the diagnosis of a possible hereditary disease." - Anonymous Online Contributor
"Results from a recent clinical trial of this trial suggest that PEGylated asparaginase is safe in patients with advanced childhood leukemia. Furthermore, this study supports ongoing assessment of pegaspargase as an intravenous chemotherapy agent in pediatric patients." - Anonymous Online Contributor
"In Canada the average age of diagnosis of CML appears to be around 55.5 years, however studies done in England and the US show it is more likely to be earlier. A reason would be if more common in the Western world, but its hard to say for sure but the average age is probably in the early 50s across European nations." - Anonymous Online Contributor